|
Synonyms: Rova-T | SC0001-SCX
Compound class:
Antibody
Comment: Rovalpituzumab tesirine is an antibody-drug conjugate (ADC) that was designed to exploit the expression of the NOTCH ligand DLL3 on certain tumours for anti-cancer efficacy [1]. It is a humanized anti-DLL3 monoclonal that is linked to a pyrrolobenzodiazepine dimer toxin called tesirine (or D6.5; PubChem CID 73672523). Once the ADC is internalized, its D6.5 payload is released and causes lethal DNA damage in the target cells.
|
| References |
|
1. Lashari BH, Vallatharasu Y, Kolandra L, Hamid M, Uprety D. (2018)
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate. Drugs R D, 18 (4): 255-258. [PMID:30232719] |
|
2. Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. (2019)
DLL3: an emerging target in small cell lung cancer. J Hematol Oncol, 12 (1): 61. [PMID:31215500] |
